Table 1

Baseline Clinical Characteristics

Placebo (n = 1,175)Flosequinan (n = 1,170)
Age (yrs)65.3 ± 10.765.6 ± 10.8
Men/women941/234910/260
Left ventricular ejection fraction23 ± 723 ± 7
Etiology of heart failure (ischemic/nonischemic)637/305641/292
NYHA functional class (class III/IV)1,032/1431,025/145
Pulmonary rales (% present)22%20%
Peripheral edema (% present)32%31%
Dose of study medication at randomization (100 mg/75 mg)937/238964/206
Systolic blood pressure (mm Hg)118 ± 19118 ± 19
Heart rate (beats/min)78 ± 1279 ± 12
Weight (kg)78 ± 1778 ± 17
Serum sodium concentration (mmol/l)138 ± 4138 ± 4
Serum potassium concentration (mmol/l)4.3 ± 0.54.3 ± 0.5
Blood urea nitrogen (mg/dl)26 ± 1526 ± 16
Serum creatinine concentration (mg/dl)1.4 ± 0.41.4 ± 0.4

Values are mean ± SD, n, or %.

NYHA = New York Heart Association.